Recurrent cardiovascular events with paclitaxel-eluting versus bare-metal stents in saphenous vein graft lesions: Insights from the sos (stenting of saphenous vein grafts) trial

Tesfaldet T. Michael, Abdul Rahman R Abdel-Karim, Aristotelis Papayannis, Christopher Lichtenwalter, James A de Lemos, Owen Obel, Tayo A Addo, Michele Roesle, Donald Haagen, Bavana Venkata Rangan, Bilal Saeed, Joseph K. Bissett, Rajesh Sachdeva, Vassilios V. Voudris, Panagiotis Karyofillis, Biswajit Kar, James Rossen, Panayotis Fasseas, Peter B. Berger, Subhash BanerjeeEmmanouil S Brilakis

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The Stenting of Saphenous Vein Grafts (SOS) trial demonstrated a reduction in clinical and angiographic adverse events with paclitaxel-eluting stents (PES) compared to bare-metal stents (BMS) in saphenous vein graft (SVG) lesions, but the rate of recurrent adverse events has not been described. METHODS: We performed a post hoc, landmark analysis to evaluate the risk of event recurrence following a non-fatal initial event among the SOS trial patients (pts). RESULTS: During a median follow-up of 35 months, the 80 pts enrolled in SOS experienced a total of 78 major cardiovascular events (MACE): 51 in the BMS group and 27 in PES group. No MACE were found in 28 pts (35) while 52 pts (65) had at least one event. The initial event was death in 13 pts (16). Among the 39 pts whose initial event was not fatal, 12 (31) had one or more subsequent MACE (50 of which were definitely related to the study SVG). The mean and median number of MACE per patient was significantly higher in patients receiving BMS versus PES (1.3 ± 1.2 and 1 ± 1.26 versus 0.6 ± 0.7 and 1 ± 0.825, p ≤ 0.005 and p ≤ 0.008, respectively). The rate of a second MACE following an initial event was 17 in the PES group and 37 in the BMS group (p ≤ 0.24). Ten of 12 pts with recurrent events had received a BMS (83). Conclusion: Pts undergoing SVG stenting had a high rate of recurrent events after an initial non-fatal event. These events were often related to the target vessel and most occurred in pts who had received a BMS, further supporting the benefit of PES over BMS in SVG lesions.

Original languageEnglish (US)
Pages (from-to)216-219
Number of pages4
JournalJournal of Invasive Cardiology
Volume23
Issue number6
StatePublished - Jun 2011

Fingerprint

Saphenous Vein
Paclitaxel
Stents
Metals
Transplants

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Recurrent cardiovascular events with paclitaxel-eluting versus bare-metal stents in saphenous vein graft lesions : Insights from the sos (stenting of saphenous vein grafts) trial. / Michael, Tesfaldet T.; Abdel-Karim, Abdul Rahman R; Papayannis, Aristotelis; Lichtenwalter, Christopher; de Lemos, James A; Obel, Owen; Addo, Tayo A; Roesle, Michele; Haagen, Donald; Rangan, Bavana Venkata; Saeed, Bilal; Bissett, Joseph K.; Sachdeva, Rajesh; Voudris, Vassilios V.; Karyofillis, Panagiotis; Kar, Biswajit; Rossen, James; Fasseas, Panayotis; Berger, Peter B.; Banerjee, Subhash; Brilakis, Emmanouil S.

In: Journal of Invasive Cardiology, Vol. 23, No. 6, 06.2011, p. 216-219.

Research output: Contribution to journalArticle

Michael, TT, Abdel-Karim, ARR, Papayannis, A, Lichtenwalter, C, de Lemos, JA, Obel, O, Addo, TA, Roesle, M, Haagen, D, Rangan, BV, Saeed, B, Bissett, JK, Sachdeva, R, Voudris, VV, Karyofillis, P, Kar, B, Rossen, J, Fasseas, P, Berger, PB, Banerjee, S & Brilakis, ES 2011, 'Recurrent cardiovascular events with paclitaxel-eluting versus bare-metal stents in saphenous vein graft lesions: Insights from the sos (stenting of saphenous vein grafts) trial', Journal of Invasive Cardiology, vol. 23, no. 6, pp. 216-219.
Michael, Tesfaldet T. ; Abdel-Karim, Abdul Rahman R ; Papayannis, Aristotelis ; Lichtenwalter, Christopher ; de Lemos, James A ; Obel, Owen ; Addo, Tayo A ; Roesle, Michele ; Haagen, Donald ; Rangan, Bavana Venkata ; Saeed, Bilal ; Bissett, Joseph K. ; Sachdeva, Rajesh ; Voudris, Vassilios V. ; Karyofillis, Panagiotis ; Kar, Biswajit ; Rossen, James ; Fasseas, Panayotis ; Berger, Peter B. ; Banerjee, Subhash ; Brilakis, Emmanouil S. / Recurrent cardiovascular events with paclitaxel-eluting versus bare-metal stents in saphenous vein graft lesions : Insights from the sos (stenting of saphenous vein grafts) trial. In: Journal of Invasive Cardiology. 2011 ; Vol. 23, No. 6. pp. 216-219.
@article{b710e2bb720248d083c08c3544ddc287,
title = "Recurrent cardiovascular events with paclitaxel-eluting versus bare-metal stents in saphenous vein graft lesions: Insights from the sos (stenting of saphenous vein grafts) trial",
abstract = "The Stenting of Saphenous Vein Grafts (SOS) trial demonstrated a reduction in clinical and angiographic adverse events with paclitaxel-eluting stents (PES) compared to bare-metal stents (BMS) in saphenous vein graft (SVG) lesions, but the rate of recurrent adverse events has not been described. METHODS: We performed a post hoc, landmark analysis to evaluate the risk of event recurrence following a non-fatal initial event among the SOS trial patients (pts). RESULTS: During a median follow-up of 35 months, the 80 pts enrolled in SOS experienced a total of 78 major cardiovascular events (MACE): 51 in the BMS group and 27 in PES group. No MACE were found in 28 pts (35) while 52 pts (65) had at least one event. The initial event was death in 13 pts (16). Among the 39 pts whose initial event was not fatal, 12 (31) had one or more subsequent MACE (50 of which were definitely related to the study SVG). The mean and median number of MACE per patient was significantly higher in patients receiving BMS versus PES (1.3 ± 1.2 and 1 ± 1.26 versus 0.6 ± 0.7 and 1 ± 0.825, p ≤ 0.005 and p ≤ 0.008, respectively). The rate of a second MACE following an initial event was 17 in the PES group and 37 in the BMS group (p ≤ 0.24). Ten of 12 pts with recurrent events had received a BMS (83). Conclusion: Pts undergoing SVG stenting had a high rate of recurrent events after an initial non-fatal event. These events were often related to the target vessel and most occurred in pts who had received a BMS, further supporting the benefit of PES over BMS in SVG lesions.",
author = "Michael, {Tesfaldet T.} and Abdel-Karim, {Abdul Rahman R} and Aristotelis Papayannis and Christopher Lichtenwalter and {de Lemos}, {James A} and Owen Obel and Addo, {Tayo A} and Michele Roesle and Donald Haagen and Rangan, {Bavana Venkata} and Bilal Saeed and Bissett, {Joseph K.} and Rajesh Sachdeva and Voudris, {Vassilios V.} and Panagiotis Karyofillis and Biswajit Kar and James Rossen and Panayotis Fasseas and Berger, {Peter B.} and Subhash Banerjee and Brilakis, {Emmanouil S}",
year = "2011",
month = "6",
language = "English (US)",
volume = "23",
pages = "216--219",
journal = "Journal of Invasive Cardiology",
issn = "1042-3931",
publisher = "HMP Communications",
number = "6",

}

TY - JOUR

T1 - Recurrent cardiovascular events with paclitaxel-eluting versus bare-metal stents in saphenous vein graft lesions

T2 - Insights from the sos (stenting of saphenous vein grafts) trial

AU - Michael, Tesfaldet T.

AU - Abdel-Karim, Abdul Rahman R

AU - Papayannis, Aristotelis

AU - Lichtenwalter, Christopher

AU - de Lemos, James A

AU - Obel, Owen

AU - Addo, Tayo A

AU - Roesle, Michele

AU - Haagen, Donald

AU - Rangan, Bavana Venkata

AU - Saeed, Bilal

AU - Bissett, Joseph K.

AU - Sachdeva, Rajesh

AU - Voudris, Vassilios V.

AU - Karyofillis, Panagiotis

AU - Kar, Biswajit

AU - Rossen, James

AU - Fasseas, Panayotis

AU - Berger, Peter B.

AU - Banerjee, Subhash

AU - Brilakis, Emmanouil S

PY - 2011/6

Y1 - 2011/6

N2 - The Stenting of Saphenous Vein Grafts (SOS) trial demonstrated a reduction in clinical and angiographic adverse events with paclitaxel-eluting stents (PES) compared to bare-metal stents (BMS) in saphenous vein graft (SVG) lesions, but the rate of recurrent adverse events has not been described. METHODS: We performed a post hoc, landmark analysis to evaluate the risk of event recurrence following a non-fatal initial event among the SOS trial patients (pts). RESULTS: During a median follow-up of 35 months, the 80 pts enrolled in SOS experienced a total of 78 major cardiovascular events (MACE): 51 in the BMS group and 27 in PES group. No MACE were found in 28 pts (35) while 52 pts (65) had at least one event. The initial event was death in 13 pts (16). Among the 39 pts whose initial event was not fatal, 12 (31) had one or more subsequent MACE (50 of which were definitely related to the study SVG). The mean and median number of MACE per patient was significantly higher in patients receiving BMS versus PES (1.3 ± 1.2 and 1 ± 1.26 versus 0.6 ± 0.7 and 1 ± 0.825, p ≤ 0.005 and p ≤ 0.008, respectively). The rate of a second MACE following an initial event was 17 in the PES group and 37 in the BMS group (p ≤ 0.24). Ten of 12 pts with recurrent events had received a BMS (83). Conclusion: Pts undergoing SVG stenting had a high rate of recurrent events after an initial non-fatal event. These events were often related to the target vessel and most occurred in pts who had received a BMS, further supporting the benefit of PES over BMS in SVG lesions.

AB - The Stenting of Saphenous Vein Grafts (SOS) trial demonstrated a reduction in clinical and angiographic adverse events with paclitaxel-eluting stents (PES) compared to bare-metal stents (BMS) in saphenous vein graft (SVG) lesions, but the rate of recurrent adverse events has not been described. METHODS: We performed a post hoc, landmark analysis to evaluate the risk of event recurrence following a non-fatal initial event among the SOS trial patients (pts). RESULTS: During a median follow-up of 35 months, the 80 pts enrolled in SOS experienced a total of 78 major cardiovascular events (MACE): 51 in the BMS group and 27 in PES group. No MACE were found in 28 pts (35) while 52 pts (65) had at least one event. The initial event was death in 13 pts (16). Among the 39 pts whose initial event was not fatal, 12 (31) had one or more subsequent MACE (50 of which were definitely related to the study SVG). The mean and median number of MACE per patient was significantly higher in patients receiving BMS versus PES (1.3 ± 1.2 and 1 ± 1.26 versus 0.6 ± 0.7 and 1 ± 0.825, p ≤ 0.005 and p ≤ 0.008, respectively). The rate of a second MACE following an initial event was 17 in the PES group and 37 in the BMS group (p ≤ 0.24). Ten of 12 pts with recurrent events had received a BMS (83). Conclusion: Pts undergoing SVG stenting had a high rate of recurrent events after an initial non-fatal event. These events were often related to the target vessel and most occurred in pts who had received a BMS, further supporting the benefit of PES over BMS in SVG lesions.

UR - http://www.scopus.com/inward/record.url?scp=79958118229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958118229&partnerID=8YFLogxK

M3 - Article

C2 - 21646644

AN - SCOPUS:79958118229

VL - 23

SP - 216

EP - 219

JO - Journal of Invasive Cardiology

JF - Journal of Invasive Cardiology

SN - 1042-3931

IS - 6

ER -